Phase 3b Trial To Evaluate Safety And Immune Response (Superiority) of a Two-Dose Butantan-DV Regimen And The Standard Single Dose In Dengue-Naive Children/Adolescents and Immune Response (Non-inferiority) in a Manufacturing Facility Change (DEN-06-IB)

NCT07712926 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

1765

Enrollment

OTHER_GOV

Sponsor class

Conditions

Dengue Fever With Warning Signs

Interventions

BIOLOGICAL: Butantan-DV (IB)
BIOLOGICAL: Butantan-DV (WuXi)
OTHER: Placebo

Sponsor

Butantan Institute

Collaborators

[object Object]